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Abstract
Background: Psychotic disorders are a serious mental health problem. Intervention before the onset of psychosis
might result in delaying the onset, reducing the impact or even preventing the first episode of psychosis. This
study explores the effectiveness of cognitive behavioural therapy (CBT) in targeting cognitive biases that are
involved in the formation of delusions in persons with an ultra-high risk for developing psychosis. A single blind
randomised controlled trial compares CBT with treatment as usual in preventing or delaying the onset of
psychosis.
Method/design: All help seeking patients aged 14 to 35 years referred to the mental health services in three
regions in the Netherlands are pre-screened with the Prodromal Questionnaire during a period of two years.
Patients with a score of 18 or more on the sub-clinical positive symptoms items (45 items in total) will be assessed
with the Comprehensive Assessment of At Risk Mental State (CAARMS). In a different pathway to care model all
referrals from the mental health services in Amsterdam to the specialized psychosis clinic of the Academic Medical
Centre in Amsterdam are also assessed with the CAARMS. The primary outcome is the transition rate to psychosis
according to the CAARMS-criteria. Group differences will be analysed with chi-square tests and survival analyses.
Discussion: CBT is a highly tolerated treatment. The psycho-educational CBT approach may prove to be a
successful strategy since most people with an At Risk Mental State (ARMS) are distressed by odd disturbing
experiences. Giving explanations for and normalising these experiences may reduce the arousal (distress) and
therefore may prevent people from developing a catastrophic delusional explanation for their odd experiences and
thus prevent them from developing psychosis.
Screening the entire help-seeking population referred to community mental health services with a two-stage strat-
egy, as compared with traditional referral to a specialist clinical psychosis centre, might detect more ultra-high-risk
(UHR) patients. This type of screening could be implemented in mental health care as routine screening. The trial is
registered at Current Controlled trials as trial number ISRCTN21353122.
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In recent decades, the number of studies on early detec-
tion and intervention in psychosis has increased expo-
nentially. In the UK [1,2], Australia [3], Norway [4] and
the Netherlands [5], specialized programs have been
developed for first psychotic episode patients. An unex-
pected finding in a seminal study was the identification
of a group of help-seeking young people with sub
threshold psychotic symptoms that made a transition to
psychosis [6]. This phase prior to a first episode of psy-
chosis, retrospectively called the prodromal period,
begins with the first changes in behaviour and lasts until
the onset of the first psychotic episode [7]. The prodro-
mal period can be characterized by various mental state
features, including non-specific symptoms such as
depressed mood and anxiety, negative signs and symp-
toms as well as sub-threshold or attenuated psychotic
symptoms [6]. However, the term “prodromal” is not
always correct in prospective investigations. After all,
only in the at risk people who actually develop a full-
blown psychosis, the symptoms can be defined as ‘pro-
dromal’. The majority of individuals who share the same
sub-clinical symptoms will recover spontaneously or
have persistent sub-clinical symptoms [8] without a
transition into psychosis. Instead of putatively prodro-
mal, in prospective studies the subjects are referred to
as being at ultra high risk (UHR) or having an At Risk
Mental State (ARMS) of developing psychosis.
Yung and McGorry were the first to develop opera-
tional criteria to detect people at ultra high risk of
developing psychosis, resulting in the Comprehensive
Assessment of At Risk Mental State (CAARMS) scale
[8]. At first about 40% of the people with ARMS made a
transition to psychosis within a year [8,9]. However,
more recent studies find lower transition rates (declining
to only 16% transition to psychosis at 24 months)
[10,11].
The identification of people at high risk for developing
psychosis has been replicated in several studies in Aus-
tralia, Europe and the USA [12-15]. People with an
ARMS experience (mild) symptoms, are often help-seek-
ing and frequently suffer psychosocial impairment and
disability [6]. Therefore one important aspect of the
ARMS is that it is a status in which an intervention
could be delivered to prevent transition. Detection of
people with ARMS is therefore required. When people
do make a transition then the potential duration of
untreated psychosis is probably short. Previous research
has shown that a shorter delay in treating the first epi-
sode of psychosis is associated with a better outcome
[16]. Intervening before the first psychotic episode can
thus be a valuable treatment option. The aim is reduc-
tion of high risk symptoms and to try to prevent or
delay the onset of psychosis as well as a reduction of
suffering from psychological impairments [13].
Several intervention studies have been performed in
the ARMS-group [3,12,14,15,17]. Interventions in these
studies include prescribing drugs (anti-psychotics or
others), cognitive behavioural therapy (CBT) or a com-
bination of these treatments. One study delivers a com-
plete treatment package to the patients [15]. These
studies suggest that an intervention may reduce the
transition to psychosis in the short term. Recently pub-
lished reviews on interventions in people at high risk for
developing psychosis concluded that the effects of inter-
ventions are currently indecisive, implying that more
research is necessary [18,19].
Aim
The objective of this study is to test a manualised CBT
aimed at reducing the transition rate to psychosis and
to reduce the number of patients with persistent ARMS-
symptoms. This CBT is largely based on the work of
French and Morrison [14,20,21] who developed a pro-
mising intervention for reducing or postponing the tran-
sition to psychosis in the short term. The intervention is
enriched with information on cognitive biases and exer-
cises to learn to correct these biases.
Methods/Design
Design
This study is a randomized controlled trial comparing
treatment as usual (TAU) with an add-on cognitive
behavioural therapy (CBT) targeted at the prevention of
psychosis. The main outcome measure is the number of
participants who develop florid psychosis within eigh-
teen months. The secondary outcome is the reduction
of the persistence of sub clinical symptoms.
The assessors are blinded to the research condition by
not being able to check the patient status. The success
of blinding is checked by having the assessors guess the
presumed condition of the subject at each major
assessment.
The design of this study has been approved by the
Dutch Union of Medical-Ethics Trial Committees for
mental health organizations. The trial will be conducted
in compliance with the ‘Declaration of Helsinki’ (amend-
ment of Edinburgh, 2000).
Participants
All patients aged 14 to 35 years referred to the mental
health services in The Hague, Rivierduinen (Leiden and
surroundings) and the province of Friesland in the
Netherlands will be pre-screened with the Prodromal
Questionnaire [22] over a period of two years. Patients
with a score above the cut-off point of 18 on the
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assessed with the CAARMS [8]. Furthermore, all
patients with a suspicion of a psychotic development
referred by the mental health services in Amsterdam to
the specialized early psychosis clinic of the department
of Psychiatry at the Academic Medical Centre will be
assessed with the CAARMS. Participants are eligible if
the following criteria are met: a) age 14 to 35 years; b) a
genetic risk or CAARMS-scores in the range of At Risk
Mental State (See table 1, 2, 3); and c) an impairment in
social functioning, (a SOFAS- score [23] of 50 or less
and/or a drop in SOFAS score of 30%.). Patients are
excluded if they meet any of the following criteria: a)
current or previous usage of antipsychotic medication
more than 15 mg Haloperidol equivalent; b) severe
learning impairment; c) problems due to organic condi-
tion; d) insufficient competence in the Dutch language;
e) history of psychosis.
Participation is voluntary. Informed consent is given in
writing and with personal signatures. Persons under 16
years also require informed consent from a parent. Par-
ticipants may withdraw their informed consent at any
time, without any consequences for their treatment.
Randomisation
Randomisation will be stratified by site, to rule out fac-
tors concerning the institutions, therapists and habitat.
The random allocation lists are generated by a web-
based automated randomization system. To guarantee a
numeric balance across conditions the randomisation
will be performed separately for each research site, in
random permuted blocks of ten. The allocation list will
be kept in a remote secure location and an independent
person randomly allocates the included patients. Patients
are randomised after providing informed consent. The
randomisation status is confirmed by fax to the rando-
misation bureau by the different sites.
Power calculation
We calculated power on an expected transition rate of
35 percent over eighteen months with a 50 percent
reduction of transitions in the CBT-group. The sample
we need for a 2-tailed test of the proportions with an
alpha of .05 and a power of .80 is 2 × 93 for the
reduction of the transition to psychosis and 2 × 82 for
the persistence of ARMS and 2 × 91 for the transition
into psychosis. A conservative estimate of the drop-out
rate is twenty percent per year in schizophrenia
research [24]. With an estimated 30 percent drop-out
over 18 months, we decided to include 240 persons in
the trial. Interventions to minimize drop-outs are flex-
ibility to location of therapy (the appointment can be
at their home-address or some times by telephone or
webcam), sending Christmas- and Birthday cards every
year. For the participants that end up in the CBT-
treatment group there is also the possibility for web-
cam therapy. All the participants that complete the
study will have a financial compensation for expenses
made.
Intervention
Participants in the control condition will receive treat-
ment as usual (TAU) for the mental problems that
they are seeking help for (e.g., depression, ADHD or
anxiety disorder). The subjects in the intervention
group will receive TAU plus a manualised cognitive
behavioural therapy (CBT). The intervention protocol,
based on the protocol from the British intervention
trial [20,21], is a cognitive behavioural intervention
that aims to reduce symptoms, normalises psychosis-
like experiences and prevents a catastrophic appraisal
of the psychotic-like symptoms from occurring. The
idea is that the final common pathway from ARMS to
psychosis is largely based on catastrophising the psy-
chotic-like symptoms which are then worsened by a
high level of emotional arousal. When the appraisals
become fixed and frightening, delusions are formed.
The therapy manual in this study is enriched with
eight sessions of psycho-education and behavioural
experiments with cognitive biases that play a role in
the development of delusions and hallucinations.
Table 1 group 2a Attenuated psychotic symptoms,
Sub-threshold intensity
Intensity Frequency
Unusual Thought Content 3-5 3-6
Non-bizarre Ideas 3-5 3-6
Perceptual Abnormalities 3-4 3-6
Disorganised Speech 4-5 3-6
Table 2 group 2b Attenuated psychotic symptoms,
sub-threshold frequency
Intensity Frequency
Unusual Thought Content 6 3
Non-bizarre Ideas 6 3
Perceptual Abnormalities 5-6 3
Disorganised Speech 6 3
Table 3 group 3, BLIPS Group
Intensity Frequency
Unusual Thought Content 6 4-6
Non-bizarre Ideas 6 4-6
Perceptual Abnormalities 5-6 4-6
Disorganised Speech 6 4-6
Symptoms occur less than one week and resolve spontaneously
Rietdijk et al. Trials 2010, 11:30
http://www.trialsjournal.com/content/11/1/30
Page 3 of 9Normalising the odd experiences as a result of percep-
tual and reasoning biases is supposed to reduce the
emotional arousal and over-involvement with the
experiences. Catastrophic delusional interpretation of
the unsettling experiences is then probably prevented.
Behavioural experiments and homework exercises
teach people to tolerate psychosis-like experiences and
reduce emotional discomfort. The intervention consists
of a maximum of 25 sessions within a six-month per-
iod. All therapists are psychologists or consultant psy-
chiatrists experienced in CBT with psychotic patients.
They are trained in using the protocol and are offered
supervision every two weeks during the course of the
trial. During the two-hour supervised sessions, audio-
taped sessions are discussed and rated on the Cogni-
tive Therapist Scale [25]. Another part of the super-
vised sessions is dedicated to case formulation and
trouble shooting of difficult cases.
Measurements
(See also table 4 for measurement moments and
instruments)
Subjects participate in the study for 18 months. At
baseline and at six-month intervals, participants are
assessed with the full CAARMS [8]. During these major
measurement sessions, participants are also assessed
with secondary outcome measures and mediators and
moderators. In between the major assessments partici-
pants are monitored with a subset of the CAARMS (the
first four scales) to assess a possible transition to psy-
chosis. The minor assessments are scheduled at months
2, 4, 9 and 15.
Instruments
The following instruments are used:
1. The Prodromal Questionnaire (authorized Dutch
translation by M. van der Gaag, R. Klaassen, L. Wunder-
ink) [22] will be used to screen patients for psychosis-
proneness in the general help-seeking population and is
a 92-item self-reporting lifetime questionnaire, rated on
a two point scale (’agree’ and ‘disagree’.) Of these items,
45 apply in the case of possible sub-clinical positive
symptoms. When maximizing the true positive cases,
Loewy et al. found a cut-off score of eight symptoms at
t h ep o s i t i v es u b s c a l ep r e d i c t i v ef o ra nA R M So nt h e
SIPS (a CAARMS look-alike) with a sensitivity of 90%
and a specificity of 48% in a population that was
referred because of suspected prodromal state [22].
Since we expect more false positives in the general help-
s e e k i n gp o p u l a t i o n ,t h ec u t - o f fs c o r ef o rt h eE D I E -
screening is higher [26]. Patients are invited for a further
structured clinical interview when the total score of
positive symptoms exceeds 18.
2. The Comprehensive Assessment of At Risk Mental
State (CAARMS [8], authorised Dutch version by M.
van der Gaag, J. van der Werf, L. Wunderink, A. Malda,
R. Klaassen) [8] is a semi-structured interview that
assesses sub-clinical psychotic symptoms in the last year
before assessment. Both intensity and frequency of the
symptoms are assessed, in order to dimensionally distin-
guish between not at risk, ARMS and psychosis (see
table 1, 2, 3). The CAARMS has a good reliability. High
scores on the CAARMS are predictive for transition
into psychosis with a relative risk of 12.44 (95% CI =
1.5 - 103.41, p = 0.0025). An ARMS predicts psychosis
Table 4 measurements
Measurements T0: baseline T6: end of the intervention T12: Follow up T18: follow up Transition
CAARMS X X X X x
BDI X X X X -
SIAS X X X X -
EQ5D x X X X -
PBIQ-R x X X X -
MANSA x X X X -
CDS x Xx
Verbal Fluency x X X X -
Medication check x X X X x
Blood sample x - - - -
SCAN interview x - - - x
PANSS - - - - x
PSYRATS - - - - x
Treatment check - - - - x
CAARMS = Comprehensive Assessment of At Risk Mental State; BDI = Beck Depression Inventory; SIAS = Social Interaction Anxiety Scale; EQ5D = Euroqol-5D;
PBIQ-R = Personal Beliefs about Illness Questionnaire-Revised; MANSA = Manchester Short Assessment of Quality of Life; CDS = The Calgary Depression Scale;
SCAN = Schedules for Clinical Assessment in Neuropsychiatry; PANSS = Positive and Negative Syndrome Scale; PSYRATS = Psychotic Symptom Rating Scales.
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ficity (91%), positive predictive value (80%) and negative
predictive value (94%) [9,25].
3. Drug and alcohol use are assessed with the Compo-
site International Diagnostic Interview (CIDI) [27]. The
CIDI is a comprehensive, fully standardized instrument
for assessing mental disorders according to the defini-
tions and criteria of ICD-10 and DSM-IV. Good reliabil-
ity and validity of the CIDI have been reported with all
Kappa coefficients above .5 for reliability and above .7
for validity [28].
4. Semantic verbal fluency is assessed with a subtest of
t h eG r o n i n g e rI n t e l l i g e n c eT e s t ,at e s tt h a ti sp a r to fa
Dutch set of intelligence tests comparable to the Wechs-
ler [29]. Participants have to name as many animals as
possible in one minute. Schizophrenia patients do have
more difficulties with tests like this compared to
depressed patients and healthy controls, due to cognitive
problems [30] F(2,63) = 3.8 p < .05. A poor result on
this test could be a predictor for schizophrenia [31].
5. Depression is assessed with the Dutch translation of
the Beck Depression Inventory second edition (BDI-II-
NL) [32]. The BDI is a 21-item self-report questionnaire,
which assesses the presence and severity of depressive
symptoms. The score ranges from 0 - 63; a high score
reflects more severe depression. The BDI-II is positively
correlated to the Hamilton Depression Scale (Pearson
r = .71). Also the test-retest reliability and the internal
consistency show high rates (Pearson r = .93 and
a = .91 respectively)
6. The Calgary Depression Scale (CDS) [33] is an 8-
item interview that assesses depressive symptoms inde-
pendent of the negative symptoms of schizophrenia with
a goodness-of-fit index of 0.89 and a root square resi-
dual of 0.07. The internal reliability was good (a 0.85).
The CDS shows weak statistically significant associations
with the negative symptoms on the PANSS (0.33)
7. The Social Interaction Anxiety Scale (SIAS) [34] is a
20-item self-report questionnaire for social anxiety.
Total scores range from 0 to 80. A high score on the
SIAS reflects more severe social phobia. The SIAS dis-
criminates significantly (p < .001) between social anxiety
and other anxieties and healthy controls. High internal
reliability (a ranges from .88 - .94) and test-retest relia-
bility (a = .92) is reported for all scales.
8. Ethnic identity is assessed with the Dutch version of
the ICSEY (International Comparative Study of Ethno
Cultural Youth) Scale of Ethnic and National Identity
[35,36]. This is a 10-item self-report questionnaire,
which assesses ethnic and national affirmation, sense of
belonging and feelings about being a group member.
Each item is rated on a 5-point scale, ranging from
‘strongly disagree’ (1) to ‘strongly agree’ (5). No informa-
tion about reliability and validity is reported.
9. The Personal Beliefs about Illness Questionnaire-
Revised (PBIQ-R) [37] assesses the subjective appraisal
of the illness. It is a self-report questionnaire with five
subscales: 1) loss, 2) humiliation, 3) shame, 4) attribu-
tion of behaviour to self or to illness and 5) entrapment
in psychosis.
10. The Euroqol-5D [38] assesses quality of life. It is a
self-report questionnaire and measures general health-
related quality of life. The list contains five dimensions
(mobility, self-care, usual activities, pain and anxiety/
depression). Each item score ranges from no to extreme
problem level. Good reliability and validity are reported
for use within a schizophrenic population [38].
11. Manchester Short Assessment of Quality of Life
(MANSA) [39]. The MANSA was developed as a slightly
modified instrument for assessing quality of life and
satisfaction with specific lifed o m a i n s .T h es e l f - r e p o r t
questionnaire contains 16 items, which are rated on a 6-
point scale. High face and construct validity was
reported for assessing quality of life (coefficients above
.82 for all domains). The measured quality of life isn’t
specifically illness or symptom related and therefore
could be used for persons with several mental illnesses
[39].
12. Genetic material will be derived from blood or
saliva.
13. The Positive And Negative Syndrome Scale
(PANSS) [40] is a 30 item structured interview that was
developed for the assessment of positive (7 items) and
negative (7 items) symptoms as well as general psycho-
pathology (16 items) over the past two weeks. The
PANSS uses 7-point Likert type scales. A study with 101
Schizophrenia patients [33] found the three scales to be
normally distributed and found evidence of reliability
and stability for the positive and negative scales (a .73
and .83, p < .001). The general psychopathology scale
has a high internal consistency (a .79, p < .001)
14. The Psychosis Rating Scale (PSYRATS) [41]con-
sists of two subscales that assess auditory hallucinations
(11 items) and delusions (6 items). Inter-rater reliability
is good, with coefficients in the range of .79 to 1.00.
Validity was checked by comparing the PSYRATS with
the Psychiatric Assessment (KGV) scale and the PANSS.
Significant relationships were found for hallucinations
and delusional disruption reported at the KGV, PANSS
and PSYRATS [41].
15. The Dutch version of the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN 2.1) [42] will be
used to assess the DSM-IV disorder status at baseline
and when a transition to psychosis occurs. The SCAN
2.1 is a semi-structured, diagnostic interview for DSM-
IV and ICD-10 designed by the World Health organiza-
tion and translated into Dutch by Giel and Nienhuis
[42]. This interview assesses all kind of symptoms
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mood disorders, anxiety disorders, eating disorders, psy-
chotic disorders and cognitive decline. The reliability of
this instrument is qualified as moderate to substantial.
Diagnosis and non-diagnosis were recognised with a
sensitivity of 86% percent and a specificity of 99%. Test-
retest reliability was significant for diagnosis (k = .64).
16. Social Demographic Questionnaire (SDQ):
T h es o c i o d e m o g r a p h i cq u e stionnaire is developed by
the researchers to assess socio-demographic factors in
our study that may play a role in the development of a
psychosis based on previous research and know risk fac-
tors for schizophrenia. The items are grouped by type:
1. General: e.g. Current residence; Birth; Relationship
status; Household; Previous residences.
2. Education: e.g. number of years full-time; training
completed; duplication number; highest level achieved;
highest level completed; total numbers of education
years; special education; cito-score.
3. Current situation: e.g. currently education; Num-
ber of months been successful in training last year; Paid
job; Number of months been working successfully last
year.
4. DSM-IV: e.g. have you ever received a psychiatric
diagnosis? If yes, what diagnosis?
5. Medication: e.g. have you ever received medica-
tion? If yes, what medications?
6. Bullying: e.g. Have you been bullied in the past; at
what age it started and stopped; Seriousness of
harassment?
7. Family data (Hetero-history): e.g. General; Educa-
tional history of family.
8. Family history: e.g. familial psychiatric disorders;
what degree of family.
9. Pregnancy: e.g. drugs, alcohol, smoking, anaemia
during pregnancy; unwanted pregnancy; duration; age of
mother at birth; APGAR-score; Birth weight; breastfeed-
ing in baby time.
10. Head injury: e.g. involving injuries?
Measurement of transition
The primary outcome measure is the transition to psy-
chosis, as defined by the CAARMS criteria [8] (see
table 5).
After transition to psychosis, participants are assessed
with the PANSS [40] and the PSYRATS [41], to rate the
severity of symptoms. They are also assessed with the
SCAN 2.1 [42] interview for diagnosis according to
DSM-IV criteria.
Fidelity checks
The inter-rater reliability of the CAARMS assessments
will be fine-tuned every three months in a Group wise
assessment and discussion of role-played cases. The
reliability of each rater is assessed by monthly indepen-
dent ratings of written reports of a CAARMS interview.
The inter-rater reliability of the assessment of the fide-
lity of therapists in delivering the manualised therapy is
fine-tuned monthly in a Group wise assessment of audio
taped sessions. The fidelity of each individual therapist
is assessed by a sample of five audio-taped therapy ses-
sions rated independently by five different assessors.
Analyses
To determine baseline balance, several variables that are
proven to be risk factors will be assessed, such as sever-
ity of ARMS-symptoms [43], heredity [44], growing up
in a big city, stress and unhealthy behaviour of mother
during pregnancy [45], migration and feelings of discri-
mination [35,36] and alcohol and drug use, including
cannabis use [46]. If the baseline balance is disturbed,
the analyses will be corrected for risk factors for transi-
tion to psychosis.
Missing data will be imputedb yE M - a l g o r i t h m .E M -
algorithm recovers the complete factor loadings con-
siderably better than simple imputation techniques
[47,48].
Group differences will be analysed by unadjusted chi-
square. Pearson’s chi-square tests will be performed to
analyse gender differences between the transition group
and the non-transition group, Comparisons will be ana-
lysed on intention-to-treat, using the Statistical Package
for the Social Sciences (SPSS for windows, version 17).
Multiple logistic regression analyses will be used to
explore which factors predict transition to psychosis
within the UHR-group. To examine the effects of CBT
on the positive symptoms reported on the first four
scales of the CAARMS, analysis of co-variance will be
used.
Survival analyses will be used to measure time to tran-
sition and risk factors for developing a first episode psy-
chosis. We will conduct Kaplan-Meier curves to explore
the cumulative probability of developing psychosis with
inclusion in the study as entry point and last follow-up
assessment after 18 months as the end point.
We will use the Mann-Whitney test to examine if
people who made a transition scored significantly higher
on the CAARMS and the SOFAS compared to patients
who did not make a transition. We considered p-values
less than 0.05 to be statistically significant.
Table 5 Psychosis threshold due to CAARMS
Intensity Frequency
Unusual Thought Content 6 4-6
Non-bizarre Ideas 6 4-6
Perceptual Abnormalities 5-6 4-6
Disorganised Speech 6 4-6
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Nowadays, research increasingly focuses on early detec-
tion of patients with an At Risk Mental State. The
objective is to delay the onset of psychosis or possibly
even prevent a psychotic episode. A better understand-
ing of the pre-psychotic phase is necessary to optimise
preventive interventions. This study is a pilot for the
implementation of early detection and intervention
teams in the Netherlands and is of interest for the gen-
eral mental health field, because indicated prevention
for this target population is not available. The study
design has a number of important strengths and limita-
tions, as described below.
The evidence for CBT in the prevention of psychosis
is still inconclusive. Only one previous study by Morri-
son and French [14] assessed the use of CBT in people
with an ARMS. All the other studies, compared the con-
trol group with either a medication group or a com-
bined medication and CBT group [3,12,14,15]. The
present study has much more power than the above-
cited study to examine the efficacy of CBT in the pre-
vention of psychosis. Our aim is to test an intervention
that aims to delay or to prevent the transition into psy-
chosis and to reduce the persistence of ARMS. The
study compares treatment as usual (TAU) with TAU
p l u sam a n u a l i s e dC B T .I ti sp a r t l yat w i ns t u d yo f
another large trial in the United Kingdom. A number of
outcome measures are identical in both cases and we
can pool the data afterwards to increase power even
more. An important strength in this study is its power
to generate conclusive answers on the possibility of pre-
vention in psychosis.
There is a growing concern regarding the use of anti-
psychotic medication when patients potentially may not
need them. Current international guidelines do not sup-
port antipsychotic medication in the prevention of psy-
chosis. Medication can have serious side-effects and it is
not yet known how long medication should be prescribed
in preventing psychosis [49]. Treating people at risk with
exclusively psychological means (CBT + education) could
b eav a l u a b l ea n dm o r eb e n i g na l t e r n a t i v et op h a r m a -
cotherapy. By providing an explanation for their odd
experiences people can come to terms with these experi-
ences. If CBT is effective in ARMS, then important goals
in mental health care can be accomplished. The use of a
benign time-limited intervention in the early stages will
be well tolerated, while antipsychotic medication is not
very well tolerated because of side-effects.
A prospective study found that 17.5% of the Dutch
population has at least one psychotic feature on the CIDI
[50,51]. But not all are at high risk of developing psycho-
sis. It is not so much the experiencing of the sub clinical
symptoms per se, but the distress associated with these
experiences that increase the risk of transformation into
psychosis. An at risk mental state becomes psychosis
when the interpretation of the sub clinical symptoms
becomes fixed and emotionally stressful. Normalising
these experiences and giving realistic explanations might
reduce the emotional arousal as a result of these disturb-
ing experiences and may prevent people from adhering
to a catastrophic delusional understanding of their unu-
sual experiences. The exposure to other risk factors, such
as urbanisation, trauma or cannabis use also increases
the probability of psychotic transition [50,51]. The study
can help to build a neuropsychiatric model of ARMS and
inform whether cognitive biases are indeed causally
involved in the formation of delusions.
All the intervention studies compared a specific inter-
vention group with monitoring assignments. This study,
on the other hand, compares two active treatment con-
ditions; it can determine the specificity of the CBT
intervention on cognitive biases. The TAU condition
targets the reduction of symptoms and emotional dis-
comfort of the ‘co morbid’ disorders and the CBT con-
dition additionally targets cognitions about the sub
clinical symptoms and the cognitive biases that are
involved in delusion formation. If psychosis formation is
driven by emotional arousal, than both treatment condi-
tions will reduce the transition rate. In that case a speci-
fic intervention is obsolete, as treating the co morbid
disorder will take away enough emotional arousal to
prevent a transition into psychosis. A weakness is that
we cannot demonstrate the efficacy of treating the co
morbid disorder on preventing transitions, because a
no-treatment control group is lacking.
A possible strength is the two-stage screening proce-
dure used to detect subjects at risk. Screening the entire
help-seeking population referred to community mental
health services with a two-stage strategy, can potentially
detect more ARMS patients by uncovering at risk cases
that would normally never be referred. Many pre-psy-
chotic symptoms are not recognised during the regular
referral process. Because we do not want to miss any
patients, we probably will not only detect late prodromal
patients, but also early prodromal patients. Therefore,
this two-stage screening method will detect more ARMS
patients than the existing referrals to the specialized
clinic, but probably at the expense of more false posi-
tives. The referred patients are more likely to be late
prodromal than the people recruited by screening.
Screening with a highly specific screening tool elimi-
nates most of those not at risk in the first stage. The
selected percentage undergoes the second stage of
screening with the CAARMS interview. In this enriched
sample of (more) psychosis-prone individuals the assess-
ment instruments will probably have a better predictive
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expect about 3.5% of the help-seeking population will
have psychotic-like experiences and will have an at-risk
mental state. In the selected group we expect the transi-
tion rate to be 25 to 35 percent over an 18 month per-
iod. If this two-stage screening process proves to be
successful, this type of screening could be implemented
in routine mental health care.
Another strength of our study is that it has a strong
external and internal validity. Since this trial is imple-
mented in a mental health setting, the results will
immediately be relevant for clinical practice. All partici-
pants receive treatment in a regular outpatient treat-
ment centre in the same way they would have received
treatment if they were not enrolled in the study. The
internal validity is fine-tuned by supervision of the
therapists every two weeks. The researchers and
research assistants have supervision every three months.
The internal validity is measured by the inter-rater relia-
bility of the CAARMS; the therapy is monitored regu-
larly and reliable and valid instruments are used.
In conclusion, the study may be of great importance
for the development and implementation of early detec-
tion and prevention of psychosis. We expect that the
two-stage screening method, as compared to traditional
referral to a specialist clinical psychosis centre, will con-
tribute to the detection of more UHR patients. Addi-
tionally, educating people at risk on cognitive biases and
treating these with CBT could be a successful strategy.
Most people with ARMS are involved in a search for a
plausible explanation for their unsettling experiences.
Normalising these experiences, providing benevolent
explanations and limiting exposure to known risk fac-
tors will probably reduce the arousal and prevent people
from adhering to a catastrophic delusional explanation
for their strange experiences. We have reason to hope
that the intervention will delay or prevent the onset of
psychosis and lower the burden and anxiety caused by
sub clinical symptoms.
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